- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00020670
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
A Phase I Study of Vaccination With Autologous CD40-Activated Acute Lymphoblastic Leukemia Cells
Aperçu de l'étude
Description détaillée
OBJECTIVES Primary
- To determine feasibility of generating a cellular vaccine composed of CD40-activated autologous ALL cells
- To determine feasibility of vaccine administration according to the proposed schedule
- To determine toxicity of vaccination with CD40-activated autologous ALL cells
Secondary
- To assess ALL-specific immunity following vaccination
- To assess the generation of immunity to control antigens
- To develop preliminary information on effect vaccination on tumor response
Type d'étude
Inscription (Réel)
Phase
- Première phase 1
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- B-cell acute lymphoblastic leukemia
- Disease involving at least 30% of bone marrow or circulating blasts
In first relapse with at least 1 of the following high-risk features:
- Age under 1 year at diagnosis
- Age over 18 years at diagnosis
- t(9;22)
- Occurrence of first relapse less than 18 months after diagnosis
- In second relapse or beyond
- Refractory disease
- Successful generation of adequate CD40 ligand-activated autologous tumor cell vaccine
- Less than 1 year since tumor cell collection
- Patients in first relapse or beyond must be ineligible for or have declined allogeneic bone marrow transplantation in order to receive study vaccine
- Patients need not be in complete remission to receive study vaccine
- Patients may have received an allogeneic hematopoetic stem cell transplant in the past
- No chemotherapy, radiotherapy, immunotherapy or immunosuppressive treatment or within 3 weeks of vaccination
- Adequate hepatic function as defined by: Bilirubin < 2x normal; AST < 3x normal; ALT < 6x normal
- Adequate renal function defined by: Creatinine < 2x normal
- <1 year since tumor cell collection
Exclusion Criteria
- Concurrent treatment as part of another therapeutic research protocol
- Pregnancy or nursing mothers
- Clinically significant pulmonary or cardiac disease
- Clinically significant autoimmune disease
- Documented infection that is active and/or not responding to therapy
- Evidence of HIV infection or known positive HIV serology
- Lansky performance scale (if <18yo) <60%, Karnofsky performance scale (if >18yo) >60%
- Once vaccination course has started: patients may not receive chemotherapy, radiotherapy, immunotherapy or immunosuppressive treatment, hematopoetic growth factors. However between tumor cell collection and vaccine administration, patients may receive non-protocol chemotherapy.
********************************************NOTE***************************************************
It is anticipated that there will be a number of patients at first relapse who are eligible for tumor cell collection and vaccine preparation but who are not eligible to receive the vaccination course. These patients will be evaluable for Objective 3.1.1 (feasibility of vaccine preparation). Patients at first relapse who are eligible for vaccine preparation but not administration should instead be treated with standard salvage regimens which may include allogeneic bone marrow transplantation according to the judgement of their primary oncologist. However, these patients represent a population at extremely high risk for progression of their disease following salvage therapy. Many of these patients will therefore be likely to fulfill eligibility criteria for vaccination in the future (i.e.
should they relapse again, or fail to enter 2nd complete remission). The majority of those patients who relapse for a second time will do so within 1 year. Those patients who become eligible for vaccination because of 2nd relapse within 1 year of tumor cell collection will receive the original vaccine and will not have further vaccine made from tumor cells collected at the time of 2nd relapse. Given the proliferative thrust of the disease in many patients, it will be advantageous to have vaccines already prepared for these patients to reduce the amount of time from 2nd relapse to vaccination.***
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: CD40 Cell Vaccination
Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination.
Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine.
Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained.
Vaccinations are administered every two weeks as outpatient therapy.
Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6.
Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
|
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Rate Of Successful Vaccine Preparation
Délai: 6 weeks
|
Vaccine preparation is a success if an adequate number of CD40 activated cells (at least 1 x 10^8 cells) can be generated.
|
6 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: W. Nicholas Haining, BM, BCh, Dana-Farber Cancer Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Leucémie
- Leucémie-lymphome lymphoblastique à cellules précurseurs
- Leucémie, Lymphoïde
- Effets physiologiques des médicaments
- Facteurs immunologiques
- Vaccins
Autres numéros d'identification d'étude
- 00-053
- P30CA006516 (Subvention/contrat des NIH des États-Unis)
- P01CA068484 (Subvention/contrat des NIH des États-Unis)
- DFCI-00053
- NCI-H01-0074
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Leucémie
-
Shenzhen Second People's HospitalRecrutementLeucémie | Myéloïde | Chronique | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | PositifChine
Essais cliniques sur CD 40
-
Michael Rapoff, Ph.D.National Institute of Neurological Disorders and Stroke (NINDS)Complété
-
Medical College of WisconsinChildren's Hospital of PhiladelphiaComplétéMaladies malignes (c.-à-d., leucémie, SMD, lymphome) | Maladies non malignes (c'est-à-dire, syndromes d'insuffisance médullaire)États-Unis
-
National Heart, Lung, and Blood Institute (NHLBI)ComplétéMaladie cardiovasculaireÉtats-Unis
-
Mashhad University of Medical SciencesRésiliéÉducation interactive sur CD
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecrutementBlessure de chute | Des chutes | Exercice d'auto-efficacité | Auto-efficacité des chutesÉtats-Unis
-
Nile TherapeuticsComplétéInsuffisance cardiaque aiguë décompenséeÉtats-Unis, Allemagne, Israël
-
Nile TherapeuticsComplétéInsuffisance cardiaque congestive
-
Shanghai Changzheng HospitalPas encore de recrutementCarcinome hépatocellulaire avancé
-
Heidelberg UniversityJohannes Gutenberg University Mainz; Heidelberg University, Psychotherapy... et autres collaborateursComplétéTrouble des conduitesAllemagne
-
Nile TherapeuticsComplété